Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.
Overview AI is speeding up drug discovery by analyzing large biological and chemical data in a short time.Deep learning and AI systems help design new drug mole ...
AI has fundamentally altered the feasibility of natural product discovery from fungal endophytes. Advances in genome sequencing, metabolomics, and systems biology have generated vast datasets, but ...
BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced another major independent validation of its AI and machine learning (ML) capabilities in a ...
Large language models (LLMs) can be broadly applied across multiple key stages in drug development: (1) Target identification and drug screening. Llama-Gram, GPCR LLM, and ProtChat systems effectively ...
The Mystra platform, developed over 10 years, offers biopharma partners proven analytical power to turn months of R&D into minutes, dramatically increasing the availability of quality genetic insights ...
The MarketWatch News Department was not involved in the creation of this content. -- Oversubscribed GBP2.5M seed round led by Ahren Innovation Capital -- Strategic collaboration with o2h to progress ...
Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results